ClinicalTrials.gg
RecruitingNCT06677645HTSHUpdated Jun 13, 2025

Evaluation of Medical and Social Care for Elderly Patients, Between Hospital and Home: TEMPORARY ACCOMMODATION Out of Hospitalization by Nursing Home and Long-Term Care Units in Ile-de-France Region

An observational study in Social Care, Medical Care and Elderly Patients, sponsored by Gérond'if. Recruiting at 10 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Gérond'if · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
258
Ages
60 Years and older
Sex
All
01

Study summary

Prospective, observational, non-interventional, comparative, multicenter RIPH3 study to investigate the impact of HTSH on length of hospital stay in referring services.

Read the detailed description

This is a multi-center study involving many hospital departments temporary accommodation at the end of hospitalization in several Nursing home/long term care units in Ile de France region. The temporary accommodation program was designed for elderly people living at home to find an accommodation solution in nursing home to meet a short-term need. Temporary accommodation beds are deployed and perpetuated in the Île-de-France region by the Regional Health Agency, physically grouped together in establishments within units with dedicated staff. The resources allocated to these beds have been increased. The aim of the study is to demonstrate the efficiency of the HTSH circuit, for elderly patients leaving hospital, in their medical and social care and the decision or not to return home. This project is supported by Regional Health Agency (ARS-IDF).

02

Conditions studied

  • Social Care
  • Medical Care
  • Elderly Patients

Keywords

  • social care
  • Tempory hospitalization
  • Elderly people
  • Medical care
  • medical-economic study
03

In context

Lead sponsor

Gérond'if is the lead sponsor of 35 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

258 subjects in the prospective group. Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.

Eligibility criteria

  • Inclusion Criteria:

    1. Patient selection criteria

      • Patient male or female at least 60 years of age, as initially defined with the Regional Health Agency, discharged from hospital,
      • Oral expression of non opposition to participation in the study, documented in the medical record by the physician,
      • Presenting a defined and feasible plan for returning home,
      • Whose social/medical situation (stabilized) does not allow an immediate return home after hospitalization.
    2. Caregiver selection criteria

      • Person with an unpaid caregiving activity for their relative in HTSH,
      • Person verbally expressing their non-opposition to participating in the study, and documented in the medical record of the patient they are helping,
      • A person who is able to understand the study questionnaires and evaluations, and is able to answer them without the help of a third party.
    3. Professional selection criteria

      • Salaried professional, nursing or not, regularly and directly involved in the HTSH circuit, whether in hospital or in nursing home / long term care units, for at least 6 months,
      • Oral expression of non opposition to participation in the study, documented by the establishment.
  • Non-inclusion Criteria:

    • Be already included in another clinical study,
    • Benefit from a legal protection measure or be unable to express their consent, in accordance with article L1121-8 of the French Public Health Code.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
258 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective group

    258 subjects in the prospective group

  • Retrospective group

    Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.

06

What researchers measure

Primary outcomes

  1. Study to investigate the impact of HTSH on length of hospital stay in referring services

    The main assessment criterion is based on the average length of stay observed at the end of the study, compared with that of the previous two years, 2021 and 2022, in the referring services.

    Time frame: 24 months

Secondary outcomes

  1. Analysis of pathways and plans for returning home

    Evaluation criteria: Calculation of the proportion of patients in the life project on admission to nursing home / long term care units and the return home at the end of the stay.

    Time frame: 24 months

  2. Analysis of HTSH patient profiles a) Proportion of eligible patients and their comorbidities b) Social profile + main reason for hospitalization of patients admitted to HTSH

    Evaluation criteria: Ratio of hospital ward activity data to pre-screening data collected during the study.

    Time frame: 24 months

  3. Analysis of discharges and patient outcomes

    Proportion of patients remaining at home in the medium term Patients' functional outcome after the trial

    Time frame: 24 months

  4. Quality of life and caregiver benefit analysis

    Quality of life assessment

    Time frame: 24 months

07

Study locations

4 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Nov 7, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Nov 20, 2026
CompletionEst.
Nov 20, 2027
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06677645
Lead sponsor
Gérond'if
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Nov 20, 2024
Primary completion
Nov 20, 2026 (estimated)
Completion
Nov 20, 2027 (estimated)
Last update
Jun 13, 2025

Study contacts

ISABELLE DUFOUR
Contact
isabelle.dufour@gerondif.org
33 (0) 185781011
Albatoul ZAKARIA, PhD
Contact
albatoul.zakaria@gerondif.org
33 (0)185 781010

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion